Successful Management of Glioblastoma Chemotherapy-Associated Dysgeusia with Gabapentin.
Karen TurcotteCharles Jean TouchetteChristian Iorio-MorinDavid FortinPublished in: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2020)
Dysgeusia is a frequent, yet underreported side effect of chemotherapy for cancer. We report here the first use of gabapentin in two glioblastoma patients who developed dysgeusia following intra-arterial administration of carboplatin or oral administration of lomustine, respectively. Treatment initiation was followed by resolution of taste alteration within weeks. Both patients reported significant improvement in their quality of life and regained weight, allowing further chemotherapy cycles. We hypothesized that in these two cases, chemotherapy impeded gustatory cells turnover and function, resulting in a gustatory "deafferentation-like" syndrome which was successfully addressed by the medication.
Keyphrases
- locally advanced
- end stage renal disease
- ejection fraction
- newly diagnosed
- induced apoptosis
- neuropathic pain
- squamous cell carcinoma
- chronic kidney disease
- body mass index
- phase ii study
- weight loss
- physical activity
- chemotherapy induced
- prognostic factors
- peritoneal dialysis
- papillary thyroid
- signaling pathway
- cell death
- oxidative stress
- bone mineral density
- patient reported outcomes
- cell proliferation
- cell cycle arrest
- case report
- adverse drug
- body weight
- pi k akt
- electronic health record